NASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis $6.81 -0.13 (-1.87%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$6.88 +0.08 (+1.10%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Fulcrum Therapeutics Stock (NASDAQ:FULC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fulcrum Therapeutics alerts:Sign Up Key Stats Today's Range$6.67▼$7.0050-Day Range$6.36▼$8.0152-Week Range$2.32▼$10.13Volume325,082 shsAverage Volume1.01 million shsMarket Capitalization$368.35 millionP/E RatioN/ADividend YieldN/APrice Target$7.57Consensus RatingModerate Buy Company Overview Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read More Fulcrum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreFULC MarketRank™: Fulcrum Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 790th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingFulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageFulcrum Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Fulcrum Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.16) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.10% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Fulcrum Therapeutics has recently decreased by 12.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.10% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Fulcrum Therapeutics has recently decreased by 12.77%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.54 News SentimentFulcrum Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,520.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulcrum Therapeutics' insider trading history. Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FULC Stock News HeadlinesAIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory AffairsAugust 6 at 7:00 PM | finance.yahoo.comFULC Fulcrum Therapeutics, Inc. - Seeking AlphaAugust 5 at 9:08 AM | seekingalpha.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 8 at 2:00 AM | Brownstone Research (Ad)FY2025 EPS Estimates for FULC Increased by Cantor FitzgeraldAugust 3, 2025 | americanbankingnews.comHC Wainwright Issues Positive Outlook for FULC EarningsAugust 3, 2025 | americanbankingnews.comBrokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $6.29August 2, 2025 | americanbankingnews.comQ3 EPS Estimate for Fulcrum Therapeutics Reduced by AnalystAugust 2, 2025 | americanbankingnews.comFulcrum Therapeutics upgraded to Buy from Neutral at H.C. WainwrightJuly 30, 2025 | msn.comSee More Headlines FULC Stock Analysis - Frequently Asked Questions How have FULC shares performed this year? Fulcrum Therapeutics' stock was trading at $4.70 at the start of the year. Since then, FULC stock has increased by 44.9% and is now trading at $6.81. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Top institutional investors of Fulcrum Therapeutics include Acadian Asset Management LLC (1.04%), Connor Clark & Lunn Investment Management Ltd. (0.63%), Simplify Asset Management Inc. (0.14%) and Aberdeen Group plc (0.11%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould and Greg Tourangeau. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings7/29/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FULC CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Fulcrum Therapeutics$7.57 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside+11.2%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.73 million Net MarginsN/A Pretax Margin-0.64% Return on Equity-31.05% Return on Assets-28.96% Debt Debt-to-Equity RatioN/A Current Ratio24.42 Quick Ratio24.42 Sales & Book Value Annual Sales$80 million Price / Sales4.60 Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book1.72Miscellaneous Outstanding Shares54,090,000Free Float50,306,000Market Cap$368.35 million OptionableOptionable Beta2.47 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:FULC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.